United Therapeutics Corporation UTHR
Set alert
At close
Pre-market · Nov 2, 8:29 AM ET
- YTD
- +22.88%
- 1 year
- +34.41%
- Open
- 600.00
- Prev close
- 593.54
- Mkt cap
- 25.68B
- Vol
- 518.24K
- Avg vol
- 716.02K
- EPS
- 27.92
- P/E
- 21.44
- Div yield
- 0.00%
More statistics
- Low
- 593.57
- High
- 609.99
- Forward P/E
- 17.67
- Beta
- 0.49
- Short ratio
- 2.42
- Inst. own
- 100.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 525.55
- 200-d avg
- 530.92
- 1y target
- 670.93
5D chart
Events in this range
- Oct 28, 2026Rating: JP Morgan · Overweight → Overweight
Signals (150)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| RSI: Overbought | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
2 days ago zacks.com
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
-
4 days ago benzinga.com
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
4 days ago zacks.com
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago benzinga.com
$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.23%. Currently, United Therapeutics has a…
5 days ago businesswire.com
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
6 days ago defenseworld.net
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average…
-
1 week ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
-
1 week ago benzinga.com
United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas
Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts…
1 week ago benzinga.com
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 23.16%. Currently, United Therapeutics has a…
-
1 week ago benzinga.com
Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725
Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
-
2 weeks ago benzinga.com
The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s…
2 weeks ago benzinga.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED)
U.S. stock futures were higher on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Tuesday's lower close.
2 weeks ago benzinga.com
Liquidia Settles Bitter Fight With United Therapeutics
Liquidia (LQDA) stock jumped 40% after settling all lawsuit battles with United Therapeutics for $380.7M. YUTREPIA PAH sales continue.
2 weeks ago benzinga.com
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
2 weeks ago benzinga.com
Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know
Liquidia shares surged 42.48% in after-hours trading after settling all pending litigation with United Therapeutics over YUTREPIA patents.
-
2 weeks ago benzinga.com
Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD
The settlement follows the September 30, 2026, ruling by the U.S. District Court for the District of Delaware (the Court) that claims 1 and 14 of U.S. Patent No. 11,826,327 (the ’327 patent) are…
-
2 weeks ago benzinga.com
Liquidia Enters Into A Global Settlement Agreement With United Therapeutics That Resolves All Pending Litigation Between The Companies; Settlement Fully Resolves Six Ongoing Lawsuits Between Liquidia And United Therapeutics; Liquidia To Pay Net $380.70M In Installments In 2026 And 2027; Liquidia Will Make A Net Payment To UTHR Of $175M Within 30 Business Days
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced…
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566
Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.
1 month ago benzinga.com
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.
-
1 month ago benzinga.com
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
Shares of United Therapeutics are rising Thursday following a federal court victory in its patent litigation against competitor Liquidia.
1 month ago benzinga.com
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.
-
1 month ago benzinga.com
BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target
BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.
-
1 month ago benzinga.com
Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing
As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order instructing the U.S. Food and Drug Administration (FDA) to withdraw approval of Liquidia’s new drug…
1 month ago benzinga.com
Why is Liquidia (LQDA) Stock Trending After Hours?
Liquidia Corp. shares gained 0.13% after hours after closing 57.19% lower following an adverse patent ruling.
1 month ago benzinga.com
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today
Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321
Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and announces Price Target of $321.
2 months ago benzinga.com
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
-
2 months ago benzinga.com
United Therapeutics Says FDA Accepts sNDA For Nebulized Tyvaso Inhalation Solution To Treat IPF
Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug…
-
2 months ago benzinga.com
United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening…
-
2 months ago benzinga.com
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.
-
3 months ago benzinga.com
United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAH
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary…
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $685 to $687.
-
3 months ago benzinga.com
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613
B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and lowers the price target from $620 to $613.
-
3 months ago benzinga.com
BETA Completes First FAA eIPP Electric Aircraft Flights, Transporting Manufactured Organs For United Therapeutics
The flights carried manufactured organs, being developed by United TherapeuticsThe flights are also the first in a series of use cases that will touch at least 26 states nationwideBETA Technologies,…
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $704
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $701 to $704.
4 months ago benzinga.com
United Therapeutics Expands Immune Therapy Pipeline With Thymmune
United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in milestone-based payments.
-
4 months ago benzinga.com
United Therapeutics Acquired Thymmune Therapeutics For $140M In Cash
United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable,…
4 months ago benzinga.com
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in transplantation.
-
5 months ago benzinga.com
United Therapeutics Says New England Journal Of Medicine Publishes Full Results Of TETON-1 Study And Combined Analyses Of TETON-1, TETON-2 Studies, Evaluating Use Of Nebulized Tyvaso For Treatment Of IPF
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity…
5 months ago benzinga.com
Baidu, Brady And 3 Stocks To Watch Heading Into Monday
U.S. stock futures down on Monday. Focus on Baidu, Brady, United Therapeutics for earnings. XP and Ryanair to report after markets close.
-
5 months ago benzinga.com
United Therapeutics Reveals FDA Clearance To Proceed With UHeart Xenotransplantation Clinical Trial
United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational…
-
5 months ago benzinga.com
United Therapeutics Enters Collaboration With Varda Space Industries To Explore The Use Of Microgravity To Develop Treatments For Rare Pulmonary Disease
Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of small molecule medicines for pulmonary disease aboard Varda's orbital manufacturing and reentry…
-
5 months ago benzinga.com
United Therapeutics Announces 12 New Data Presentations Across Its Commercial And Development Portfolio For The American Thoracic Society Conference, May 15-20
Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated…
-
5 months ago benzinga.com
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $701
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $707 to $701.
-
5 months ago benzinga.com
Wells Fargo Upgrades United Therapeutics to Overweight, Raises Price Target to $738
Wells Fargo analyst Benjamin Burnett upgrades United Therapeutics (NASDAQ:UTHR) from Equal-Weight to Overweight and raises the price target from $575 to $738.
5 months ago benzinga.com
Transcript: United Therapeutics Q1 2026 Earnings Conference Call
Transcript: United Therapeutics Q1 2026 Earnings Conference Call